BEIJING, Oct. 23, 2018 /PRNewswire/ — China Electronics Data Service Co., Ltd. (“CECD”) and WuXi AppTec announced today to set up a joint venture, CW Data, to offer one-stop big data solutions for the healthcare sector. Based on hospital medical and prescription data, CW Data will provide healthcare data solutions for pharmaceutical companies, biotechnology companies, payers, providers, policy makers, healthcare professionals and other life science industry organizations, thereby further promoting the innovation and development of the China’s healthcare ecosystem and benefiting more Chinese patients.

Relying on CECD’s National healthcare big data platform and National healthcare big data security platform and strictly complying with the National Healthcare Big Data Safety and Supervision laws and regulations to ensure multi-dimensional data security, CW Data will integrate with WuXi AppTec’s unmatched deep domain expertise in drug discovery and development to leverage highly innovative data collection, data mining and data analytics, provide end to end technology solutions and services ranging from drug discovery and development to post-marketing drug efficacy evaluation and drug distribution, and assist customers to deeply explore the needs of Chinese patients, so that more new drugs and therapies with urgent medical needs will be launched earlier in China. CW Data will build and lead the next generation of healthcare big data analytics.

“The establishment of CW Data is an important cornerstone for CECD into healthcare analytics and big data. Healthcare big data is one of the key national strategic resources. The development of various big data applications will bring profound changes in the healthcare sector. WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company. The future of CW Data is tremendous. CW Data will combine big data, cloud computing, artificial intelligence and other cutting-edge technologies to connect hospitals, insurance, disease, prescriptions, clinical, and genomics data to provide real world evidence and business insights to domestic and foreign biotechnology companies, drug distributors and medical device companies. Finally, achieve the vision of CECD – ‘Making people healthier and happier’“. said Li Shifeng, Chairman of CECD.

“This collaboration is a significant move for WuXi AppTec to strengthen our capability in medical big data industry and provide more effective solutions for the whole healthcare ecosystem with the efficient integration of hospitals’ medical data, drug research and development resources.” said Dr. Ge Li, Chairman and CEO of WuXi AppTec, “Through this collaboration, we will enable more doctors, scientists and healthcare companies by exploring more precise patient needs and more insightful healthcare data analytics, to achieve the dream that every drug can be made, every disease can be treated.”

Andy Liu, CEO of CW Data and a 20 year veteran of the healthcare industry said: “This is indeed a very special joint venture. The combination of CECD and Wuxi AppTec enables CW Data to take a leadership role in healthcare big data analytics and to drive changes that will ultimately benefit the patients. We look forward to building the future and working with other healthcare big data, AI, cloud and software companies to achieving our goals.”

About CECD

China Electronics Data Service Co., Ltd. (CECD) is a national healthcare big data group company led by China Electronics Corporation under the guidance of the National Health Commission of PRC. CECD is a National High-Tech Enterprise and Zhongguancun High-Tech Enterprise, it adheres to the principle of “safety first, data services, platform operation, ecological development” to structure two core capabilities: “Safety “and “Intelligence”.

Relies on the national team of security and informatization – China Electronics Corporation, CECD forged a full life cycle data security system with the tri-alliance of security integrated system, management and control system, and safety contingency system, based on securities of nature, process, industrial control, and data.

CECD is the main operator of the National Healthcare Big Data Center and Industrial Park (Fuzhou), the only implementation unit of the National Development and Reform Commission (hereinafter referred to NDRC) key program “Internet + Healthcare”, the co-construction unit of NDRC Healthcare Big Data Engineering Laboratory, and the Secretary General unit of the Healthcare Big Data Development and Information Security Committee of China Health Information Association (China Healthcare Big Data Industrial Alliance). As the chief initiator, CECD is the key funder of Shanghai Data Exchange Corp. Also, it established CEC Healthcare Fund and its management company – CEC Data and Finance Investment Management Co., Ltd., to build the ecosystem of healthcare big data.

About WuXi AppTec

WuXi AppTec (603259, SH) is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling over 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made, every disease can be treated.”

View original content:http://www.prnewswire.com/news-releases/china-electronics-data-and-wuxi-apptec-form-cw-data-a-joint-venture-to-offer-one-stop-healthcare-big-data-solutions-300735727.html

SINGAPORE, Oct. 23, 2018 /PRNewswire/ — AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced positive preliminary results from a recently completed Phase I study investigating the safety of AWAK PD in dialysis treatment for patients with End Stage Renal Disease (ESRD) led by the Singapore General Hospital (SGH).

AWAK PD

A world-first, the AWAK PD is a wearable and ultra-portable peritoneal dialysis (PD) system that incorporates AWAK’s patented sorbent technology to disrupt the way in which peritoneal dialysis is currently administered. The AWAK PD is a compact device that weighs less than 2 kg and enables dialysis to be performed “on-the-go”, overcoming the challenge of long hours of therapy and connection to large-size dialysis machines in hospitals and clinics currently faced by renal patients.

The sorbent technology regenerates and reconstitutes used dialysis fluid into fresh fluid while removing the uremic toxins from the spent dialysate. The AWAK PD device requires between 1.5 and 2 litres of dialysate to perform a patient’s entire daily therapy, compared with 8 to 12 litres required by traditional PD methods.

Conducted at SGH, the single-arm pilot study enrolled 15 adults between the ages of 21 and 80 undergoing regular PD treatment. Each patient had to complete 9 dialysis sessions of 3.5 hours each with AWAK PD over three continuous days.

Preliminary results show that AWAK PD was able to efficiently remove the accumulation of waste substances from the body. Patients also did not experience any serious adverse events during dialysis with AWAK PD. 

The full results from the trial are being analysed and will be announced in first half of 2019.

Suresha Venkataraya, Chief Executive Officer, AWAK Technologies, said: “We are excited by the encouraging results from this important Phase I (first-in-human) trial of AWAK PD. The findings provide positive clinical evidence of AWAK PD’s safety profile as a wearable device with the potential to truly disrupt the administration of peritoneal dialysis treatments. With the continued support of the National Medical Research Council, Singapore and Singapore General Hospital (SGH), we can now bring the technology closer to patients.

“The AWAK PD has been designed to empower ESRD patients to take control of their treatment in their own time and adapt therapy to their lifestyle rather than the other way around. We look forward to continuing our clinical work and commercialising our technology, offering an enhanced quality of life to end-stage renal disease patients worldwide.“

Dr Marjorie Foo, Principal Investigator of the AWAK PD first in human trial, said: “The number of patients with end-stage renal disease continues to climb globally, largely due to diabetes. For these patients, transplantation is the best treatment but most are on dialysis to stay alive due to the scarcity of organs. Dialysis, however, can cause much disruption to their lives. Some have even had to stop work, resulting in a loss of income.

“We are therefore heartened by the favourable results of our Phase I trial. The wearable dialysis system has the potential to not only revolutionise how peritoneal dialysis can be delivered, it also gives patients the option of ‘dialyse to live’ and not ‘live to dialyse’. This is as close as one can get to an artificial organ performing the functions of the kidney. A hospital-industry collaboration such as this is key to advancing patient care,” said Dr Foo who is also Head and Senior Consultant, Department of Renal Medicine, SGH.

Media contacts

About End-Stage Renal Disease

End stage Renal Disease (ESRD) is the fifth stage of Chronic Kidney Disease (CKD) that affects the functioning of kidneys, leading to accumulation of excess fluid and toxic wastes in the blood. People with ESRD undergo either renal transplantation or dialysis. Since renal transplantation is highly dependent on patient’s health and age, dialysis scores over as the primary treatment. It was estimated as of 2011, there were 2.7 million ESRD patients of whom 2.1 million were on dialysis. Of these 2.1 million, 10.8% of the patients are on peritoneal dialysis (PD) and the remaining 89.2% are on hemodialysis (HD)[1].

Dialysis treatment can be performed either at home, in a dialysis centre or at a hospital. In hemodialysis, blood is drawn out of the patient’s body into a synthetic filter called dialyser. In the dialyser, there are two spaces separated by a membrane, with blood passing on one side and dialysis fluid on the other side. Waste products and excess water passes from the blood through the membrane into the fluid through diffusion process. The fluid containing the waste products is then discarded while the clean blood is returned back to the patient’s body.

In peritoneal dialysis, the lining of the abdominal cavity acts like the external filter to cleanse the blood. Dialysis fluid is introduced into the abdominal cavity through a permanent tube. The fluid remains in the abdominal for a certain period of time before it is drained and discarded.

About AWAK Technologies

AWAK Technologies Pte Ltd. is a pioneering, patient-centric medical technology company with a mission to enhance the lives of dialysis patients and their caregivers by providing solutions to deliver better outcomes and improve their quality of life.

Headquartered in Singapore with an office in Burbank, California, USA, the company is dedicated to the research, development and marketing of novel, sorbent-based kidney dialysis machine for the treatment of patients with end-stage renal disease. For more information, please visit: www.awak.com

About Singapore General Hospital

Singapore General Hospital, a member of Singapore Health Services, is the public sector’s flagship hospital. Established in 1821, SGH is Singapore’s largest acute tertiary hospital with 1,700 beds and national referral centre offering a comprehensive range of 39 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research in her continual strive to provide the best care and outcomes to her patients. www.sgh.com.sg

Photo – https://photos.prnasia.com/prnh/20181023/2276139-1

SAN DIEGO and SHANGHAI, Oct. 19, 2018 /PRNewswire/ — In collaboration with Fudan University Shanghai Cancer Center and Nanfang Hospital of Southern Medical University, Singlera Genomics, a UC San Diego spinout company focused on non-invasive cancer detection, presented the results of its initial ColonES retrospective study at the 2018 American Society of Human Genetics (ASHG) Annual Meeting. ColonES utilizes targeted next-generation sequencing to screen for early stage colorectal cancer (CRC) and precancerous lesions known as advanced adenomas using methylation haplotype signatures of circulating tumor methylated DNA (ctmDNA) in blood plasma.

Detecting CRC at its earliest stages greatly improves survival rates, from 10% if detected at later stages to approximately 90% if detected earlier. “Discovering advanced adenomas, the precancerous stage of CRC, can greatly reduce the risk of CRC in the population,” said Dr. Guoxiang Cai, Professor of Surgical Oncology and Vice Director of the Department of Surgery at Fudan University Shanghai Cancer Center. “Current gold standard screening tests, such as colonoscopy or stool based tests, are uncomfortable and thus have a low compliance rate. Based on initial studies, ColonES is clearly a viable blood-based alternative which could increase CRC screening compliance.”

In the ColonES study, 1,243 patients were enrolled, including 429 healthy individuals, 204 individuals with advanced adenomas, 291 CRC stage I patients, 133 CRC stage II patients, 124 CRC stage III patients, and 102 CRC stage IV patients. These samples were matched for sex, age, neoplasm size and neoplasm location. In an independent blinded sample cohort, sensitivities of 93% for CRC and 88% for advanced adenoma were achieved with a specificity of 99%.

“These results are extremely encouraging and warrant further prospective validation,” said Yuan Gao, PhD, Cofounder and Chairman of Singlera Genomics. “The overall accuracy, cost, and convenience of ColonES could provide a viable non-invasive colon cancer screening method before colonoscopy, and ultimately save lives.”

Singlera Genomics is currently looking for collaboration partners. The company has also applied similar technology to other cancer types with high accuracy.

Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center, established in 1931 as Sino-Belgium Radium Institute, is the first comprehensive cancer hospital in China. With a history of over eight decades, the Center has taken the initiative in exploring cancer in terms of its prevention, diagnosis, treatment, and research.

Nanfang Hospital of Southern Medical University
Nanfang Hospital is the first affiliated hospital of Southern Medical University, which was founded in 1951 and became a national key university in 1979. As the earliest medical center to serve foreigners, Nanfang Hospital has admitted more than 110,000 patients from over 90 countries and regions.

Singlera Genomics Inc. (www.singlera.com)
Singlera Genomics Inc., a company focusing on non-invasive genetic diagnosis, was co-founded in July 2014 in San Diego, California. The company currently has R&D centers and business operations in both La Jolla, California, and Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation, and bioinformatics.

Logo – https://mma.prnewswire.com/media/771542/Singlera_Genomics_Logo.jpg  

Source: Singlera Genomics Inc.

AHMEDABAD, India, Oct. 22, 2018 /PRNewswire/ —

Veeda Clinical Research Pvt. Ltd., a leading independent CRO is proud to announce that our clinical (Shivalik, Ahmedabad)and Bio analytical facilities (Insignia, Ahmedabad) successfully completed second audit by NPRA (Malaysian Regulatory agency) without any major or critical observations.

This Inspection was a routine study Inspection performed by the NPRA Inspectors with the purpose to verify the compliance of the facility and study conduct to the principles of Good Clinical Practices. The audit outcome confirmed that the activities in Veeda CRO are in compliance with the SOPs and regulatory guidelines.

Veeda CRO have successfully faced 50 regulatory audits in last 13 years wherein 18 USFDA Inspections were conducted successfully in last 24 months which demonstrates our commitment levels towards Quality and Regulatory Compliance.

With an enhanced focus on ‘Right First Time’ approach, Veeda CR looks forward to a brighter future in Clinical Research Arena. These inspections are another testimony to Veeda CR’s continuous quality review and improvement measures institutionalized into the work culture.

About Veeda CRO 

Veeda CR is a full service CRO that conducts clinical research to support clients in their clinical programs. The company provides expert services in PK (pharmacokinetic) and PD (pharmacodynamics) studies in healthy volunteers; conducts patient trials in generic molecules and NCEs (new chemical entity) and undertakes research in Biopharmaceuticals. The company offers a fully integrated package which includes services on Phase I to Phase IV clinical trials in central nervous system, oncology, and other complex therapeutic areas. The company’s services also include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, and regulatory and medical writing to meet global clinical development needs.  

Contact:
Priyanka Tiwari
Priyanka.Tiwari@veedacr.com

SAN DIEGO and SHANGHAI, Oct. 19, 2018 /PRNewswire/ — Fudan University’s Taizhou Health Science Institute and Singlera Genomics, a UC San Diego spinout company focused on non-invasive early cancer detection, today announce initial results from the Taizhou Longitudinal Study (TLS) during the 2018 American Society of Human Genetics (ASHG) Annual Meeting.  An oral presentation highlighted data showing Singlera’s PanSeer assay can detect five types of cancer up to four years before conventional diagnosis using a single blood draw.

The TLS study began in 2007 collecting plasma samples from over 120,000 healthy individuals. Study participants were monitored for a 10-year period through cooperation with local hospitals and health insurance databases, allowing longitudinal information to be collected. 

Previous studies have reported that biomarker signals from early cancers are difficult to detect. By utilizing Singlera’s proprietary PanSeer assay for targeted DNA methylation haplotype next-generation sequencing, the research team was able to demonstrate early detection of colorectal, esophageal, liver, lung, and stomach cancer four years prior to disease diagnosis.  These five cancer types represent 43% of cancer mortality in the US and 74% of cancer mortality in China.

“This study for the first time demonstrates non-invasive early detection of multiple types of cancer four years before conventional diagnosis,” said Yuan Gao, Ph.D., Co-founder and Chairman of Singlera Genomics. “Many cancers are detected too late for an effective treatment option to be available; by moving the date of cancer diagnosis up by several years, cancer mortality can be significantly reduced.”

“While other studies have demonstrated that solid tumors can be non-invasively detected using blood biomarkers, previous work has mostly focused on symptomatic patients that have already been diagnosed with cancer through other means,” said Li Jin, professor at Fudan University and organizer of the longitudinal study. “By combining Singlera’s unique assays with the TLS cohort, our research team was able to show that true early detection of cancer can become a reality.”

The research team is in the process of extending this early detection approach to additional cancer types, and Singlera is currently looking for collaboration partners.

Fudan University (http://www.fudan.edu.cn/en/)
Fudan University, established in 1905, is located in Shanghai, China. The name “Fudan” originated from a famous statement, meaning unremitting effort. Fudan University comprises 17 full-time schools (including 66 specialties) and 69 departments across 4 campuses. It has 68 specialties for Bachelor’s Degree Candidates, 209 specialties for Master’s Degree Candidates, and 157 specialties for Doctoral Degree Candidates. It has nearly 44,300 students, including full-time students, students in Continuing Education or Network Education, as well as overseas students.

Singlera Genomics Inc. (www.singlera.com)
Singlera Genomics Inc., a company focusing on non-invasive genetic diagnosis, was co-founded in July 2014 in San Diego, California. The company currently has R&D centers and business operations in both La Jolla, California, and Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation, and bioinformatics.

Logo – https://mma.prnewswire.com/media/771542/Singlera_Genomics_Logo.jpg  

Source: Singlera Genomics Inc.

New image reconstruction architecture designed to support easier diagnosis to enhance workflow and user experience with innovative features and ergonomics

SINGAPORE, Oct. 21, 2018 /PRNewswire/ — Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, is showcasing its new generation of premium ultrasound system HERA W10 and prototype of a chair-type ultrasound system HERA I10 at the 28^th World Congress of the International Society of Ultrasound in Obstetrics & Gynecology (ISUOG) from October 21^st to 24^th in Singapore.

Samsung showcases premium new ultrasound systems ‘HERA W10’ and ‘HERA I10’ at ISUOG World Congress 2018.

HERA is a new premium platform which stands for Hyper-aperture Enhanced Reconstruction Architecture, incorporating Samsung’s new Crystal Architecture™ to provide advanced technology and capabilities with a new level of image quality. Samsung’s new platform combines Crystal Architecture™ with an advanced transducer technology called S-Vue™. It allows an 11-fold increase in processing power and 10 times the data transfer speed of Samsung’s previous system. It is expected to facilitate the examination of high-risk pregnancies and early diagnosis of abnormal fetus conditions.

“Samsung is proud to introduce a new premium ultrasound system HERA W10 and a form factor innovation ultrasound HERA I10, as well as solutions that greatly improve the efficiency of hospitals,” said Dongsoo Jun, President of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “Samsung will continue to provide the best solutions possible and bring meaningful changes in the healthcare industry.”

New features for Samsung’s HERA W10 ultrasound system offer clinicians an optimized workflow and more information to overcome challenges, including:

Outstanding Image Quality

• Crystal Architecture™ — Offers a superior image with single crystal probe technology S-Vue™, a new beamforming technology CrystalBeam™ and an advanced post-processing engine CrystalLive™.
• ShadowHDR™ — Provides a shadow suppressed image, especially applicable to highly attenuated regions such as fetal head and spine.
• HQ-Vision™ — Allows users get high resolution images to detect clinically important details.

New Samsung Exclusive Technologies

• MV-Flow™ — Offers a detailed view of blood flow in relation to the surrounding tissues or pathology with an enhanced spatial and temporal resolution.
• LumiFlow™ — Provides a three-dimensional visualization of continuous and volumic vascular image.

Seamless Workflow

• Wide Control Panel — Adopted rotatable control panel with a top-notch swivel mechanism.
  Allows moving range of 550mm from left to right and 219mm from top to bottom.
• Touch Customization — Allows users to easily change the position of the button on the touchscreen for each mode and feature.

In addition to HERA W10, Samsung is unveiling a prototype of HERA I10, which shares the same platform as HERA W10, but with a completely new ergonomic redesign. HERA I10 is a next-generation chair-type ultrasound system with a design that is entirely different from the industry norm that meets the unique needs of Ob/Gyn professionals. HERA I10 provides a comfortable experience for both the doctor and the patient by addressing the discomfort caused by the spacing and the position of the clinicians and eliminating the need for the patient to shift their body, as it automatically adjusts for proper positioning. It also reduces the force required to move the control panel back and forth and the resistance force on the wrist.

A new ultrasound solution SonoSync™ will also be introduced, which allows healthcare professionals to see real-time ultrasound scanning images in remote places[1]. SonoSync™ provides two-way communications through voice chatting and marking, improving accessibility. It can be installed on various devices such as smartphones, laptops and desktop PCs, allowing multilocation real-time training and education among healthcare professionals. Its Multiview feature also increases productivity by viewing multiple image scans in one screen.

For more information on Samsung’s healthcare division, its subsidiaries and products please visit https://www.samsunghealthcare.com.

About Samsung Medison

Samsung Medison is a global leading medical device company, specializing in diagnostic imaging devices. With a mission to bring health and well-being to people’s lives, the company is committed to create a new future for medical professionals and patients around the world across various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating the world’s best IT, image processing, semiconductor and communication technologies into medical devices.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.

A prototype of chair-type ultrasound system ‘HERA I10’ is being displayed at ISUOG World Congress 2018.

Photo  – https://photos.prnasia.com/prnh/20181021/2273320-1-a
Photo  – https://photos.prnasia.com/prnh/20181021/2273320-1-b

Source: Samsung BioLogics Co., Ltd.

• Liquid biopsy drawing attention for preventing the recurrence of cancer and allowing for early detection of cancers
• EDGC develops the most advanced lipuid biopsy technology

SEOUL, South Korea, Oct. 19, 2018 /PRNewswire/ — EONE-DIAGNOMICS Genome Center (EDGC), a global company in genetic analysis, has announced the release of a liquid biopsy screening service this autumn. The service is a non-invasive liquid biopsy technology which has drawn attention as the most promising advanced diagnosis technology with the development of NGS technology.

The liquid biopsy technology is a technology that Grail, Illumina Inc. spin-out, and others have raised about 1.8 billion dollars’ funds to develop it. It is useful for preventing any recurrence in patients with cancer and early detection of cancer.

The liquid biopsy screening technology is known as the most advanced liquid biopsy technology that is able to early detect various cancers with a simple blood test from people without any signs or symptoms, and it is only capable through comprehensive analysis of samples, various biomarkers measurements and precise algorithms.

EDGC has been developing the liquid biopsy technology for lung cancer, colorectal cancer and breast cancer, interworking with domestic and overseas university hospitals and has decided to commercialize it as the recent clinical experiments have excellent achievements. The liquid biopsy screening service commercialized this time would be provided to the global market through CLIA certification in the United States. Also, it would predict risk of cancers statistically and detect even microscopic factors leading to cancers, analyzing both inherent risk of cancers and acquired biomarkers simultaneously.

In these regards, EDGC has presented ‘NGS Analysis Methods and Examples for Liquid Biopsy’ at the International Symposium of Korean Society of Integrative Oncology which was held in South Korea on October 14th. The symposium covered the topic of anti-cancer immunotherapy; the Nobel Prize-winning field. In the symposium, greatest scholars such as Dr. Gary Deng of the Memorial Sloan Kettering Cancer Center in the United States and Prof. Ping-Ping Li of Peking University Cancer Hospital in China participated and discussed integrated cancer treatments. Therefore, it became a valuable opportunity for EDGC to show its liquid biopsy technology.

Ph.D. Sung Hoon Lee, a chief technology officer in charge of the development for the liquid biopsy screening technology, said that the multi-omics liquid biopsy method is an innovative method to overcome constraints and limitations of existing cancer diagnosis tests by combining protein and nucleotide sequencing analysis and performing quantitative and qualitative analysis simultaneously. He explained that it is able to provide the multi-faceted service by accumulated experiences of genomic data analysis algorithms and non-invasive prenatal diagnosis that EDGC has developed so far.

Meanwhile, Variable Signal-Amplifying Algorithm (VarSAMP), a core algorithm of the technology, and Multivariant Regression are patent-pending, and other quantitative and qualitative analysis methods and complex analysis are in preparations for patents.

Also, Lee said that the method could not only detect cancers with high accuracy but also allow accurate measurement with a little data since it maximizes sensitivity but does not lower specificity. Therefore, it has an advantage to perform accurate analysis with a much lower cost as compared to methods used by overseas competitors. He expressed high confidence about it.

After announcing the technological development, EDGC plans to perform global research and additional clinical cooperation in several countries. For this, it will recruit clinical participants from South Korea, the United States, China and so on.

With this clinical participation, EDGC will promote a campaign to prepare for a healthy 100-year-old age through early detection of cancers and apprehension of comprehensive risk.

*Multi-omics: a biological analysis approach in which the data sets are multiple omes such as genome, proteome, transcriptome, epigenome and microbiome

View original content to download multimedia:http://www.prnewswire.com/news-releases/edgc-to-launch-liquid-biopsy-screening-service-technology-for-early-detection-of-cancers-this-autumn-300734123.html

PARIS, October 19, 2018 /PRNewswire/ —

The Consumer Goods Forum (CGF) is pleased to announce the launch of the Global Health and Wellness Digital Framework, developed in partnership with Capgemini. The aim of the Framework is to provide CGF members and stakeholders with a guide to how digital can support the goal of positively impacting behavioural change to help people live healthier lives.

The new framework outlines the role that digital technology can play for companies as they build tailored roadmaps for their health initiatives. The framework includes five steps to move the goals of any individual initiative to a portfolio of prioritised interventions to help drive behavioural change.

With case studies from CGF members, including the Migros Wellbeing Journey, Walgreens Balance Rewards for Healthy Choices®, L’Oréal’s Digitising Human Experiences and Danone’s Chatbots, as well as Spoon Guru’s Artificial Intelligence-based Food Search and Discovery, and Yuka’s app to keep consumers informed about the food they eat, the Framework also provides examples of how digital is already driving positive changes in consumer behavior.

Sharon Bligh, Director, Health & Wellness, The Consumer Goods Forum, said, “Members of The Consumer Goods Forum are committed to driving positive change on a global scale. It is part of what makes us unique as an organisation. With an increased focus on digital we hope this framework will help inspire retailers and manufacturers around the world to pick up the baton and join us on this collaborative and digital journey to empower healthier people. Thank you to all CGF members who leaned in to help us co-build this with Capgemini“.

Behavioural Change and Digital as an Enabler 

Digital communications are now an essential part of everyday life and one of the most effective ways to reach consumers with accurate and personalised information. Digital is seen as a critical component for CGF members if they are to achieve their aim of taking a proactive, leadership role in empowering consumers to live healthier lives and drive shared business value, while providing transparent information and improving trust in the industry.

Kees Jacobs, Vice President, Global Consumer Products & Retail Sector, Capgemini said, “Capgemini is pleased to have partnered with The Consumer Goods Forum and its members to develop a Digital Framework that will serve as a guide for companies all over the world embarking on a transformation journey for their business. Using our knowledge and experience working with clients across the industry, we see digital playing an important role for retailers and manufacturers in enabling healthier lives.“

For more information, please see the Global Health and Wellness Digital Framework.

About The Consumer Goods Forum 

The Consumer Goods Forum (“CGF”) is a global, parity-based industry network that is driven by its members to encourage the global adoption of practices and standards that serves the consumer goods industry worldwide. It brings together the CEOs and senior management of some 400 retailers, manufacturers, service providers, and other stakeholders across 70 countries, and it reflects the diversity of the industry in geography, size, product category and format. Its member companies have combined sales of EUR 3.5 trillion and directly employ nearly 10 million people, with a further 90 million related jobs estimated along the value chain. It is governed by its Board of Directors, which comprises more than 50 manufacturer and retailer CEOs. For more information, please visit: http://www.theconsumergoodsforum.com.

About Capgemini 

A global leader in consulting, technology services and digital transformation, Capgemini is at the forefront of innovation to address the entire breadth of clients’ opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. Capgemini is driven by the conviction that the business value of technology comes from and through people. It is a multicultural company of 200,000 team members in over 40 countries. The Group reported 2017 global revenues of EUR 12.8 billion.

Visit us at http://www.capgemini.com. People matter, results count.

CHONGQING, China, Oct. 19, 2018 /PRNewswire/ — On October 16, China’s First International Seminar on Hot Springs and Climate Health Tourism was held in BeiBei, Chongqing. Hot springs and climate experts, scholars and related entrepreneurs came from various countries such as China, Italy, Russia, and Japan (in total approximately 350 attendees) came together to discuss the topic of hot springs and climate health and how to transform Chongqing into a hot springs travel destination.

This seminar was held with the theme of “Assembling the World’s Next Hot Spring Capital, Hot Springs, and Climate Health Tourism.” During the opening ceremony, Zhang Yue, a secretary of the Zhongwen Association, stated that Chongqing is striving to develop the world’s first “Hot Springs Capital” brand, inviting the World Hot Springs Organization to build a Chongqing office and transform the city into a hot springs travel destination. Chongqing actively promotes this development of their tourist economy, and, in turn, paves a new road for the development of global hot spring tourism.

Throughout the seminar, Chongqing signed a number of hot springs and climate health tourism projects. These projects cover areas such as hot springs, leisure reports, and industrial research and utilization.

In addition to the brainstorming sessions, such as the expert lectures and guest dialogues, the World Federation of Hydrotherapy and Climatotherapy (Chongqing office), Chongqing Hot Spring Tour Association, Chongqing Hot Spring Tourism Alliance and other institutions received awards.

17 experts in the field of hot springs and climate health care were officially hired as the first group of consultants for Chongqing hot spring and climate healthcare tourism during the meeting including Mr. Umberto Solimene, Mr. Giovanni Gurnari, Mr. Giorgio D’Alessandro, and Mr. Otsuka Yoshinori. Umberto Solimene, president of the World Federation of Hydrotherapy and Climatotherapy, read out the “Chongqing Consensus on World Hydrotherapy and Climatotherapy Tourism”.

These experts will provide strong intellectual support for Chongqing to build a world-class hot spring tourist city and spa resort, and help the industry innovate with their cutting-edge academic philosophies.

Chongqing is rich in hot spring geothermal resources. At present, the known hot spring distribution area amounts to 10,000 square kilometers with 146 hot spring mines, 560 million cubic meters of geothermal water per year, and 400,000 cubic meters of scientific exploitable capacity per day. The current exploitable capacity accounts for only 20.2 % of the reasonable exploitable capacity. Chongqing was named the world’s first ” Hot Springs Capital” as early as 2012.

Beibei District, one of the top five hot spring tourism destinations in China, is known as the hometown of Chinese hot springs for its unique hot spring resources endowed by nature. Taking advantage of this symposium, Chongqing will speed up the building of “World Hot Springs Valley” and make every effort toward upgrading the “Hot Springs Capital”. 

View original content:http://www.prnewswire.com/news-releases/chinas-first-international-seminar-on-hot-springs-and-climate-health-tourism-kicked-off-on-oct-16-in-beibei-chongqing-300734223.html